Home Articles Issues and Perspectives The Molecules Nigeria Does not Make – And Why it Matters

The Molecules Nigeria Does not Make – And Why it Matters

0
85
Dr Lolu Ojo

When the naira weakens, medicine prices rise. Not because Nigerian pharmacists are inefficient. Not because local manufacturers lack commitment.

But because Nigeria imports nearly every molecule that makes its medicines work.

At the heart of every tablet, capsule, injection, suppository, cream and infusion lies the Active Pharmaceutical Ingredient (API), the chemical substance responsible for therapeutic effect. Without APIs, formulation plants are merely packaging centres.

And today, Nigeria imports almost all of them. This is not just a pharmaceutical issue. It is an industrial, economic, and national security question.

A $250 billion global industry concentrated elsewhere

The global API market was valued at roughly $220–250 billion in 2023 and is projected to exceed $350 billion by 2030. Demand is driven by chronic diseases, expanding generic medicines, oncology treatments, and biologics.

Yet production is heavily concentrated. India supplies around one-fifth of global generic APIs and dominates finished generic exports. China provides approximately 40–50 per cent of the world’s key starting materials and chemical intermediates, the building blocks of APIs.

The United States and Europe retain high-value regulated production, but even they rely substantially on Asian chemical supply chains. This architecture is efficient, but fragile. During COVID-19, export restrictions in Asia triggered supply disruptions across Africa. What appeared to be a diversified global pharmaceutical system revealed itself as highly concentrated upstream.

For countries without domestic API capacity, vulnerability is structural.

Nigeria: Scale without backward integration

Nigeria is West Africa’s largest pharmaceutical market, with over 220 million people and an estimated industry value of $2–2.5 billion. Yet:

70–75 per cent of medicines are imported (NAFDAC’s current figure is 60 per cent).

Nearly 100 per cent of APIs are imported.

Local manufacturers operate largely at formulation and packaging level.

In effect, Nigeria assembles medicines whose core components are sourced abroad.

The implications are significant:

Every foreign exchange crisis transmits directly into drug pricing.

Every global shipping disruption threatens availability.

Every geopolitical tension introduces risk into national health supply.

When the naira depreciates, drug prices rise, not as a policy choice, but as a structural inevitability.

Why has Nigeria not entered API manufacturing?

Because API manufacturing is not simply another factory. It is capital-intensive, energy-intensive, environmentally regulated, and ecosystem-dependent.

A modest small-molecule API facility can require $50–150 million in capital investment. It demands:

Continuous, stable power supply

Advanced chemical synthesis capability

Industrial-scale wastewater treatment

Strict Good Manufacturing Practice (GMP) compliance

Nigeria’s electricity grid currently generates roughly 4,000–5,000 megawatts for over 220 million people. By comparison, India’s total installed power capacity exceeds 400,000 megawatts. Energy costs in Nigeria can be two to three times higher than in India, a decisive disadvantage in chemical manufacturing.

Furthermore, India’s API success did not happen overnight. It evolved from decades of petrochemical development, process chemistry training, state-backed incentives, and regulatory maturation.

API production is not an isolated investment decision. It is an ecosystem outcome.

Africa’s wider vulnerability

Africa accounts for less than three per cent of global pharmaceutical manufacturing output. Across Sub-Saharan Africa, between 70 and 90 per cent of medicines are imported. The continent captures minimal value in the global pharmaceutical supply chain.

The African Continental Free Trade Area (AfCFTA) offers an opportunity for regional integration. But integration without industrial production merely enlarges a trading bloc; it does not create pharmaceutical sovereignty. The real opportunity lies in pooled demand.

Nigeria alone may struggle to achieve sufficient scale for many APIs. But ECOWAS collectively represents a far larger and more viable demand base. Regional procurement coordination could create the volume threshold required for competitiveness. This is not diplomatic idealism. It is industrial mathematics.

The strategic choice: Ambition or discipline?

Total pharmaceutical self-sufficiency is unrealistic. No modern economy is entirely self-sufficient. But strategic vulnerability is a choice.

Nigeria does not need to manufacture every API. That would be economically irrational. However, selective backward integration into a small number of high-volume, essential molecules is achievable, if approached with discipline. Such a strategy would require:

Government-backed demand guarantees

Concessional industrial financing

Dedicated pharmaceutical industrial zones with guaranteed power

Regulatory harmonisation across ECOWAS

Without coordinated policy, private investors will not assume the scale of risk involved.

Why this matters beyond pharmacists

This conversation is not only for industry stakeholders. It affects:

Inflation

Foreign exchange stability

Industrial diversification

Job creation

National resilience

Oil built yesterday’s Nigeria. But the next global disruption may not respect oil wealth. It will test supply chain depth. Nations that cannot produce the molecules that sustain life do not control their health destiny.

The questions before policymakers

Should APIs be designated a strategic industrial sector?

Should the Bank of Industry establish a targeted API financing window?

Should ECOWAS create a pooled procurement and production framework?

Should sovereign investment funds support pharmaceutical backward integration?

These are not technical questions. They are economic strategy questions.

A moment for deliberate design

Formulation capacity was Nigeria’s first pharmaceutical chapter. Backward integration, selective, disciplined, and regionally coordinated, could be the second. If we continue to treat APIs as an invisible import line in trade statistics, the next global shock will again expose our fragility. The molecules Nigeria does not make may yet define the limits of its industrial sovereignty.

The choice is deliberate or default. And the default is dependency.

Dr Lolu Ojo is a consultant pharmacist in Lagos.

LEAVE A REPLY

Please enter your comment!
Please enter your name here